Twist Bioscience Corp (TWST) stock price, news and key stats

About Twist Bioscience Corp

Latest TWST news

• Twist Bioscience (TWST) Rallied as AI and Pharma Drive DNA Demand
  Yahoo Finance · Sep 8, 2026

  Twist Bioscience (TWST) experienced a significant rally, gaining over 15% on Wednesday, driven by heightened demand for DNA synthesis technologies amid advancements in artificial intelligence and pharmaceutical applications. The surge in TWST's stock price was further fueled by a positive announcement from AI startup Anthropic, which has implications for the biotech sector as companies increasingly leverage AI for drug discovery and development. The company’s recent fiscal 2026 third-quarter financial results showcased robust sequential revenue growth, prompting an upward revision of its fiscal guidance. Twist Bioscience's innovative semiconductor-based platform for DNA synthesis positions it favorably in a market that is increasingly integrating AI to enhance research capabilities. As the demand for scalable and efficient solutions in drug discovery rises, TWST is well-positioned to capitalize on these trends, potentially attracting further investment and interest from market participants. The rally in TWST's stock not only reflects investor optimism about the company's prospects but also signals a broader trend within the biotech sector, where companies that effectively harness AI technologies are likely to see increased valuations. As the intersection of AI and life sciences continues to evolve, investors will be closely monitoring how companies like Twist Bioscience adapt and innovate in this rapidly changing landscape.